DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair

Progress in Nucleic Acid Research and Molecular Biology

Volumn 71, Issue , 2002, Pages 1-68

  Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; DRUG DERIVATIVE; HIGH MOBILITY GROUP B1 PROTEIN; ORGANOMETALLIC COMPOUND; PLATINUM COMPLEX; RUTHENIUM;

AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DNA ADDUCT; DNA REPAIR; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; REVIEW; STEREOISOMERISM;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CISPLATIN; DNA ADDUCTS; DNA REPAIR; DNA, NEOPLASM; HMGB1 PROTEIN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; ORGANOMETALLIC COMPOUNDS; ORGANOPLATINUM COMPOUNDS; RUTHENIUM; STEREOISOMERISM;

EID: 0036357321     PISSN: 00796603     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0079-6603(02)71040-4     Document Type: Review

References (241)

1. B Rosenberg L Van Camp J.E Trosko V.H Mansour Platinum compounds: A new class of potent antitumor agents Nature 222 1969 385 386
2. E Wong C.M Giandomenico Current status of platinum-based antitumor drugs Chem. Rev. 99 1999 2451 2466
3. P.J O'Dwyer J.P Stevenson S.W Johnson Clinical status of cisplatin, carboplatin, and other platinum-based antitumor drugs B Lippert Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug 1999 VHCA, Wiley-VCH Zürich/Weinheim 31 72
4. G Giaccone Clinical perspectives on platinum resistance Drugs 59 2000 9 17
5. N.P Johnson J.-L Butour G Villani F.L Wimmer M Defais V Pierson V Brabec Metal antitumor compounds: The mechanism of action of platinum complexes Prog. Clin. Biochem. Med. 10 1989 1 24
6. E.R Jamieson S.J Lippard Structure, recognition, and processing of cisplatin-DNA adducts Chem. Rev. 99 1999 2467 2498
7. J Reedijk Improved understanding in platinum antitumour chemistry Chem. Commun. 1996 801 806
8. A Gelasco S.J Lippard Anticancer activity of cisplatin and related complexes M.J Clarke P.J Sadler Metallopharmaceuticals I. DNA Interactions 1999 Springer Berlin 1 43
9. Z.J Guo P.J Sadler Metals in medicine Angew. Chem. Int. Ed. 38 1999 1513 1531
10. D.B Zamble S.J Lippard The response of cellular proteins to cisplatin-damaged DNA B Lippert Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug 1999 VHCA, Wiley-VCH Zürich/Weinheim 73 110
11. 195Pt NMR kinetic and mechanistic studies of cis -diamminedichloroplatinum and trans -diamminedichloroplatinum(II) binding to DNA J. Am. Chem. Soc. 112 1990 6860 6871
12. A.M.J Fichtinger-Schepman J.L Van der Veer J.H.J Den Hartog P.H.M Lohman J Reedijk Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation Biochemistry 24 1985 707 713
13. A Eastman The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes Pharmacol. Ther. 34 1987 155 166
14. V Brabec Chemistry and structural biology of 1,2-interstrand adducts of cisplatin L.R Kelland N.P Farrell Platinum-Based Drugs in Cancer Therapy 2000 Humana Press Inc., Totowa, NJ 37 61
15. O Vrana V Boudny V Brabec Superhelical torsion controls DNA interstrand crosslinking by antitumor cis -diamminedichloroplatinum(II) Nucleic Acids Res. 24 1996 3918 3925
16. V Brabec V Kleinwächter J.L Butour N.P Johnson Biophysical studies of the modification of DNA by antitumour platinum coordination complexes Biophys. Chem. 35 1990 129 141
17. A Eastman M.M Jennerwein D.L Nagel Characterization of bifunctional adducts produced in DNA by trans -diamminedichloroplatinum(II) Chem.-Biol. Interact. 67 1988 71 80
18. V Brabec M Leng DNA interstrand cross-links of trans -diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues 3rd ed. Proc. Natl. Acad. Sci. U.S.A. 90 1993 5345 5349
19. M Boudvillain R Dalbies C Aussourd M Leng Intrastrand cross-links are not formed in the reaction between transplatin and native DNA: Relation with the clinical inefficiency of transplatin Nucleic Acids Res. 23 1995 2381 2388
20. M Leng A Schwartz M.J Giraud-Panis Transplatin-modified oligonucleotides as potential antitumor drugs L.R Kelland N.P Farrell Platinum-Based Drugs in Cancer Therapy 2000 Humana Press Clifton, NJ 63 85
21. N.P Johnson J.-P Macquet J.L Wiebers B Monsarrat Structures of adducts formed between [Pt(dien)CI]Cl and DNA in vitro Nucleic Acids Res. 10 1982 5255 5271
22. J.L Leroy E Charretier M Kochyian M Gueron Evidence from base-pair kinetics for two types of adenine tract structures in solution: their reaction to DNA curvature Biochemistry 27 1988 8894 8898
23. J Ramstein R Lavery Base pair opening pathways in B-DNA J. Biomol. Struct. Dyn. 7 1990 915 933
24. A Schwartz M Sip M Leng Sodium cyanide-A chemical probe of the conformation of DNA modified by the antitumor cis -diamminedichloroplatinum(II) J. Am. Chem. Soc. 112 1990 3673 3674
25. M.A Lemaire A Schwartz A.R Rahmouni M Leng Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis -diamminedichloroplatinum(II) and DNA 3rd ed. Proc. Nail. Acad. Sci. U.S.A. 88 1991 1982 1985
26. D.Z Yang A.H.J Wang Structural studies of interactions between anticancer platinum drugs and DNA Prog. Biophys. Mol. Biol. 66 1996 81 111
27. K.M Comess C.E Costello S.J Lippard Identification and characterization of a novel linkage isomerization in the reaction of Trans -diamminedichloroplatinum(II) with 5′-d(TCTACGCGTTCT) Biochemistry 29 1990 2102 2110
28. R Dalbies M Boudvillain M Leng Linkage isomerization reaction of intrastrand cross-links in Trans -diamminedichloroplatinum(II)-modified single-stranded oligonucleotides Nucleic Acids Res. 23 1995 949 953
29. R Dalbies D Payet M Leng DNA double helix promotes a linkage isomerization reaction in Tans-diamminedichloroplatinum(II)-modified DNA 3rd ed. Proc. Natl. Acad. Sci. U.S.A. 91 1994 8147 8151
30. M Boudvillain M Guerin R Dalbies T Saison-Behmoaras M Leng Transplatin-modified oligo(2′-O-methyl ribonucleotide)s: A new tool for selective modulation of gene expression Biochemistry 36 1997 2925 2931
31. J.- Malinge M Leng Interstrand cross-links in cisplatin or transplatin-modified DNA B Lippert Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug 1999 Verlag Helvetica Chimica Acta, Wiley-VCH Zürich/Weinheim 159 180
32. K Aupeix-Scheidler S Chabas L Bidou J.-P Rousset M Leng J.-J Toulme Inhibition of in vitro and ex vivo translation by a transplatin-modified oligo(2′-O-methylribonucleotide) directed against the HIV-1 gag-pol frameshift signal Nucleic Acids Res. 28 2000 438 445
33. M Leng V Brabec DNA adducts of cisplatin, transplatin and platinum-intercalating drugs K Hemminki A Dipple D.E.G Shuker F.F Kadlinbar D Segerbäck H Bartoch DNA Adducts: Identification and Biological Significance 1994 International Agency for Research on Cancer Lyon 339 348
34. N.P Davies L.C Hardman V Murray The effect of chromatin structure on cisplatin damage in intact human cells Nucleic Acids Res. 28 2000 2954 2958
35. J.T Millard E.E Wilkes cis- and Trans -Diamminedichloroplatinum(II) interstrand crosslinking of a defined sequence nucleosomal core particle Biochemistry 39 2000 16,046 16,055
36. J Reedijk Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem. Rev. 1999 2499 2510
37. K.J Barnham M.I Djuran P.d.S Murdoch J.D Ranford P.J Sadler L.-Methionine increases the rate of reaction of 5′-guanosine monophosphate with anticancer drug cisplatin: mixed-ligand adducts and reversible methionine binding J. Chem. Soc., Dalton Trans. 1995 3721 3726
38. 7 in S -guanosyl-L-homocysteine (sgh) J. Chem. Soc. Chem. Commun. 1993 1397 1398
39. 2+ model Inorg. Chem. 38 1999 1450 1455
40. C.J Van Garderen H Van den Elst J.H Van Boom J Reedijk L.P.A Van Houte A double-stranded DNA fragment shows a significant decrease in double-helix stability after binding of monofunctional platinum amine compounds J. Am. Chem. Soc. 111 1989 4123 4125
41. V Brabec J Reedijk M Leng Sequence-dependent distortions induced in DNA by monofunctional platinum(H) binding Biochemistry 31 1992 12,397 12,402
42. V Brabec V Boudny Z Balcarova Monofunctional adducts of platinum(H) produce in DNA a sequence-dependent local denaturation Biochemistry 32 1994 1316 1322
43. M.V Keck S.J Lippard Unwinding of supercoiled DNA by platinum ethidium and related complexes J. Am. Chem. Soc. 114 1992 3386 3390
44. Z Balcarova V Brabec DNA modified by platinum derivatives cannot adopt the A-form Biochim. Biophys. Acta 867 1986 31 35
45. + Biophys. Chem. 35 1990 179 188
46. J.M Teuben C Bauer A.H.J Wang J Reedijk Solution structure of a DNA duplex containing a cis -diammineplatinum(II) 1,3-d(GTG) intrastrand cross-link, a major adduct in cells treated with the anticancer drug carboplatin Biochemistry 38 1999 12,305 12,312
47. H.F Huang L.M Zhu B.R Reid G.P Drobny P.B Hopkins Solution structure of a cisplatin-induced DNA interstrand cross-link Science 270 1995 1842 1845
48. F Coste J.-M Malinge L Serre W Shepard M Roth M Leng C Zelwer Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: Hydration at the platinated site Nucleic Acids Res. 27 1999 1837 1846
49. V Brabec M Sip M Leng DNA conformational distortion produced by site-specific interstrand cross-link of trans -diamminedichloroplatinum(II) Biochemistry 32 1993 11,676 11,681
50. F Paquet M Boudvillain G Lancelot M Leng NMR solution structure of a DNA dodecamer containing a transplatin interstrand GN7-CN3 cross-link Nucleic Acids Res. 27 1999 4261 4268
51. M.F Anin M Leng Distortions induced in double-stranded oligonucleotides by the binding of cis -diamminedichloroplatinum(II) or trans -diamminedichloroplatinum(II) to the d(GTG) sequence Nucleic Acids Res. 18 1990 4395 4400
52. A.L Pinto S.J Lippard Sequence-dependent termination of in vitro DNA synthesis by cis - and trans -diamminedichloroplatinum(II) 3rd ed. Proc. Natl. Acad. Sci. U.S.A. 82 1985 4616 4620
53. G Villani U Hubscher J.-L Butour Sites of termination of in vitro DNA synthesis on cis -diamminedichloroplatinum(II) treated single-stranded DNA: A comparison between E. coli DNA polymerase I and eucaryotic DNA polymerases alpha Nucleic Acids Res. 16 1988 4407 4418
54. K.M Comess J.N Burstyn J.M Essigmann S.J Lippard Replication inhibition and translesion synthesis on templates containing site-specifically placed cis -diamminedichloroplatinum(II) DNA adducts Biochemistry 31 1992 3975 3990
55. V Murray H Motyka P.R England G Wickham H.H Lee W.A Denny W.D McFadyen The use of Taq DNA polymerase to determine the sequence specificity of DNA damage caused by cis -diamminedichloroplatinum(II), acridine-tethered platinum(II) diammine complexes or 2 analogues J. Biol. Chem. 267 1992 18,805 18,809
56. V Murray H Motyka P.R England G Wickham H.H Lee W.A Denny W.D McFadyen An investigation of the sequence-specific interaction of cis -diamminedichloroplatinum(II) and four analogues, including two acridine-tethered complexes, with DNA inside human cells Biochemistry 31 1992 11,812 11,817
57. M Coluccia F Nassii F Loseto A Boccarelli M.A Marigio D Giordano F.P Intini P Caputo G Natile A trans -platinum complex showing higher antitumor activity than the cis congeners J. Med. Chem. 36 1993 510 512
58. V Murray J Whittaker M.D Temple W.D McFadyen Interaction of 11 cisplatin analogues with DNA: Characteristic pattern of damage with monofunctional analogues Biochim. Biophys. Acta 1354 1997 261 271
59. D Burnouf M Daune R.P Fuchs Spectrum of cisplatin-induced mutations in Escherichia coli 3rd ed. Proc. Natl. Acad. Sci. U.S.A. 84 1987 3758 3762
60. K.J Yarema S.J Lippard J.M Essigmann Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis -diamminedichloroplatinum(II) Nucleic Acids Res. 23 1995 4066 4072
61. G Villani N.T Le Gac J.-S Hoffmann Replication of platinated DNA and its mutagenic consequences B Lippert Cisplatin. Chemistry and biochemistry of a leading anticancer drug 1999 VHCA, Wiley-CH Zürich/Weinheim 135 157
62. C.M Sorenson A Eastman Mechanism of cis -diamminedichloroplatinum(II)-induced cytotoxicity-Role of G2 arrest and DNA double-strand breaks Cancer Res. 48 1988 4484 4488
63. G Chu Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair J. Biol. Chem. 269 1994 787 790
64. M.J Allday G.J Inman D.H Crawford P.J Farrell DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective EMBO J. 14 1995 4994 5005
65. Y Corda C Job M.F Anin M Leng D Job Transcription by eucaryotic and prokaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis -diamminedichloroplatinum(II) Biochemistry 30 1991 222 230
66. Y Corda M.F Anin M Leng D Job RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis -diamminedichloroplatinum(II) Biochemistry 31 1992 1904 1908
67. C Cullinane S.J Mazur J.M Essigmann D.R Phillips V.A Bohr Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage Biochemistry 38 1999 6204 6212
68. Y Corda C Job M.-F Anin M Leng D Job Spectrum of DNA-platinum adduct recognition by prokaryotic and eukaryotic DNA-dependent RNA polymerases Biochemistry 32 1993 8582 8588
69. J.A Mello S.J Lippard J.M Essigmann DNA adducts of cis -diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo Biochemistry 34 1995 14,783 14,791
70. J Mymryk E Zaniewski T Archer Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo 3rd ed. Proc. Natl. Acad. Sci. U.S.A. 92 1995 2076 2080
71. P Jordan M Carmo-Fonseca Cisplatin inhibits synthesis of ribosomal RNA in vivo Nucleic Acids Res. 26 1998 2831 2836
72. D.J Beck R.R Brubaker Effect of cis -platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair-deficient mutants of Escherichia coli J. Bacteriol. 116 1973 1247 1252
73. J Brouwer P Van de Putte A.M.J Fichtinger-Schepman J Reedijk Base-pair substitution hotspots in GAG and GCG nucleotide sequences in E. coli K-12 induced by cis -diamminedichloroplatinum(II) 3rd ed. Proc. Natl. Acad. Sci. U.S.A. 78 1981 7010 7014
74. D.J Beck S Popoff A Sancar W.D Rupp Reactions of the UVRABC excision nuclease with DNA damaged by diamminedichloroplatinum(II) Nucleic Acids Res. 13 1985 7395 7412
75. E Janovska V Kleinwächter Inactivation effect of platinum(H) compounds on strains of Escherichia coli Stud. Biophys. 114 1986 187 192
76. D.B Zamble D Mu J.T Reardon A Sancar S.J Lippard Repair of cisplatin-DNA adducts by the mammalian excision nuclease Biochemistry 35 1996 10,004 10,013
77. A.C.M Plooy M Van Dijk F Berends P.H.M Lohman Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis -diamminedichloroplatinum(II) Cancer Res. 45 1985 4178 4184
78. F.J Dijt A.M.J Fichtinger-Schepman F Berends J Reedijk Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts Cancer Res. 48 1988 6058 6062
79. Y Fujiwara M Tatsumi M.S Sasaki Cross-link repair in human cells and its possible defect in Fanconi's anemia cells J. Mot Biol. 113 1977 635 649
80. P Calsou P Frit B Salles Repair synthesis by human cell extracts in cisplatindamaged DNA is prefentially determined by minor adducts Nucleic Acids Res. 20 1992 6363 6368
81. D Fink S Nebel S Aebi H Zheng B Cenni A Nehme R.D Christen S.B Howell The role of DNA mismatch repair in platinum drug resistance Clin Cancer Res. 56 1996 4881 4886
82. S Aebi D Fink R Gordon H.K Kim H Zheng J.L Fink S.B Howell Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells Clin. Cancer Res. 3 1997 1763 1767
83. S.W Johnson K.V Ferry T.C Hamilton Recent insights into platinum drug resistance in cancer Drug Resistance Updates 1 1998 243 254
84. J.T Drummond A Anthoney R Brown P Modrich Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line J. Biol. Chem. 271 1996 19645 19648
85. D Fink S Nebel S Aebi A Nehme S.B Howell Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin Int. J. Oncol. 11 1997 539 542
86. K.V Ferry D Fink S.W Johnson S Nebel T.C Hamilton S.B Howell Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells Biochem. Pharmacol. 57 1999 861 867
87. R.B Ciccarelli M.J Solomon A Varshavsky S.J Lippard In vivo effects of cis and trans -diamminedichloroplatinum(II) on SV 40 chromosomes: Differential repair, DNA-protein cross-linking, and inhibition of replication Biochemistry 24 1985 7533 7540
88. J Zlatanova J Yaneva S.H Leuba Proteins that specifically recognize cisplatin-damaged DNA: A clue to anticancer activity of cisplatin FASEB J. 12 1998 791 799
89. R Reeves Structure and function of the HMGI(Y) family of architectural transcription factors Environ. Health Persp. 108 2000 803 809
90. J.O Thomas A.A Travers HMG1 and 2, and related ‘architectural’ DNA-binding proteins Trends Biochem. Sci. 26 2001 167 174
91. S.U Dunham S.J Lippard DNA sequence context and protein composition modulate HMG-domain protein recognition of ciplatin-modified DNA Biochemistry 36 1997 11428 11436
92. S.M Cohen Y Mikata Q He S.J Lippard HMG-Domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts Biochemistry 39 2000 11,71 11776
93. D.S Pilch S.U Dunham E.R Jamieson S.J Lippard K.J Breslauer DNA sequence context modulates the impact of a cisplatin 1,2-d(GpG) intrastrand cross-link an the conformational and thermodynamic properties of duplex DNA J. Mol. Biol. 296 2000 803 812
94. C Hofr N Farrell V Brabee Thermodynamic properties of duplex DNA containing a site-specific d(GpG) intrastrand crosslink formed by an antitumor dinuclear platinum complex Nucleic Acids Res. 29 2001 2034 2040
95. U.M Ohndorf M.A Rould Q He C.O Pabo S.J Lippard Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins Nature 399 1999 708 712
96. M Stros Two mutations of basic residues within the N-terminus of HMG-1 B domain with different effects on DNA supercoiling and binding to bent DNA Biochemistry 40 2001 4769 4779
97. J Kasparkova V Brabec Recognition of DNA interstrand cross-links of cis -diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins Biochemistry 34 1995 12,379 12,387
98. L.G Marzilli J.S Saad Z Kuklenyik K.A Keating Y.H Xu Relationship of solution and protein-bound structures of DNA duplexes with the major intrastrand cross-link lesions formed on cisplatin binding to DNA J. Am. Chem. Soc. 123 2001 2764 2770
99. A.T Yarnell S Oh D Reinberg S.J Lippard Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin J. Biol. Chem. 276 2001 25,736 25,741
100. G Orphanides T Lagrange D Reinberg The general transcription factors of RNA polymerase II Genes Dev. 10 1996 2657 2683
101. P Vichi F Coin J.P Renaud W Vermeulen J.H.J Hoeijmakers D Moras J.M Egly Cisplatin- and UV damaged DNA lure the basal transcription factor TFIID/TBP EMBO J. 16 1997 7444 7456
102. F Coin P Frit B Viollet B Salles J.M Egly TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease Mol. Cell. Biol. 18 1998 3907 3914
103. S.M Cohen E.R Jamieson S.J Lippard Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 1,2-cross-links Biochemistry 39 2000 8259 8265
104. T Ise G Nagatani T Imamura K Kato H Takano M Nomoto H Izumi H Ohmori T Okamoto T Ohga T Uchiumi M Kuwano K Kohno Transcription factor Y -box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen Cancer Res. 59 1999 342 346
105. T Ohga K Koike M Ono Y Makino Y Itagaki M Tanimoto M Kuwano K Kohno Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light Cancer Res. 56 1996 4224 4228
106. J Yaneva S.H Leuba K van Holde J Zlatanova The major chromatin protein histone H1 binds preferentially to cis -platinum-damaged DNA 3rd ed. Proc. Natl. Acad. Sci. U.S.A. 94 1997 13,448 13,451
107. E.G Paneva N.C Spassovska K.C Grancharov J.S Zlatanova J.N Yaneva Interaction of histone Hl with cis -platinum modified DNA Z. Naturforsch. 53c 1998 135 138
108. M Bustin R Reeves High-mobility-group chromosomal proteins: Architectural components that facilitate chromatin function Prog. Nucleic Acid Res. Mol. Biol. 54 1996 35 100
109. J Zlatanova K van Holde The linker histones and chromatin structure: New twists Prog. Nucleic Acid Res. Mol. Biol. 52 1996 217 259
110. J Zlatanova K Van Holde Binding to four-way junction DNA: A common property of architectural proteins? FASEB J. 12 1998 421 431
111. M Missura T Buterin R Hindges U Hiibscher[ J Kasparkova V Brabec H Naegeli Initiation of mammalian nucleotide excision repair: Double-check probing of DNA helix conformation by repair protein XPA and replication factor RPA EMBO J. 20 2001 3554 3564
112. C.J Jones R.D Wood Preferential binding of the Xeroderma Pigmentosum group A complementing protein to damaged DNA Biochemistry 32 1993 12,096 12,104
113. H Asahina I Kuraoka M Shirakawa E Morita N Miura I Miyamoto E Ohtsuka Y Okada K Tanaka The XPA protein is a zinc metalloprotein with an abilito to recognize various kinds of DNA-damage Mutat. Res. 315 1994 229 237
114. I Kuraoka E.H Morita M Saijo T Matsuda K Morikawa M Shirakawa K Tanaka Identification of a damaged-DNA binding domain of the XPA protein Mutat. Res. 362 1996 87 95
115. J.J Turchi K.M Henkels I.L Hermanson S.M Patrick Interactions of mammalian proteins with cisplatin-damaged DNA J. Inorg. Biochem. 77 1999 83 87
116. N.X Xu L Pasa-Tolic R.D Smith S.S Ni B.D Thrall Electrospray ionization-mass spectrometry study of the interaction of cisplatin-adducted oligonucleotides with human XPA minimal binding domain protein Anal. Biochem. 272 1999 26 33
117. T Hey G Lipps G Krauss Binding of XPA and RPA to damaged DNA investigated by fluorescence anisotrophy Biochemistry 40 2001 2901 2910
118. C.K Clugston K McLaughlin M.K Kenny R Brown Binding of human single-stranded-DNA binding-protein to DNA damaged by the anticancer drug cis -diammine-dichloroplatinum(II) Cancer Res. 52 1992 6375 6379
119. S.M Patrick J.J Turchi Human replication protein a preferentially binds cisplatindamaged duplex DNA in vitro Biochemistry 37 1998 8808 8815
120. S.M Patrick J.J Turchi Replication protein A (RPA) binding to duplex cisplatindamaged DNA is mediated through the generation of single-stranded DNA J. Biol. Chem. 274 1999 14,972 14,978
121. 4-methylthymine, or the cisplatin-d(GpG) adduct 3rd ed. Proc. Nail. Acad. Sci. U.S.A. 93 1996 6443 6447
122. J.A Mello S Acharya R Fishel J.M Essigmann The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin Chem. Biol. 3 1996 579 589
123. M Yamada E O'Regan R Brown P Karran Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins Nucleic Acids Res. 25 1997 491 495
124. Z Özer J.T Reardon D.S Hsu K Malhotra A Sancar The other function of DNA photolyase: Stimulation of excision repair of chemical damage to DNA Biochemistry 34 1995 15,886 15,889
125. J.J Turchi K Henkels Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase J. Biol. Chem. 271 1996 13,861 13,867
126. J.J Turchi K.M Henkels Y Zhou Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK Nucleic Acids Res. 28 2000 4634 4641
127. A.I.H Murchie D.M.J Lilley T4 endonuclease VII cleaves DNA containing a cisplatin adduct J. Mol. Biol. 233 1993 77 82
128. C.M Riva Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism Anticancer Res. 20 2000 4463 4471
129. P Jordan M Carmo-Fonseca Molecular mechanisms involved in cisplatin cytotoxicity Cell. Mol. Life Sci. 57 2000 1229 1235
130. P.M O'Connor J Jackman I Bae T.G Myers S Fan M Mutoh D.A Scudiero A Monks E.A Sausville J.N Weinstein S Friend A.J Fornace K.W Kohn Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents Cancer Res. 57 1997 4285 4300
131. J Kasparkova S Pospisilova V Brabec Different recognition of DNA modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53 J. Biol. Chem. 276 2001 16,064 16,069
132. P.J Perry L.R Kelland Telomeres and telomerase: targets for cancer chemotherapy? Expert Opinion on Therapeutic Patents 8 1998 1567 1586
133. A.M Burger J.A Double D.R Newell Inhibition of telomerase activity by cisplatin in human testicular cancer cells Eur. J. Cancer 33 1997 638 644
134. Y Kondo S Kondo Y Tanaka T Haqqi P.B Barna J.K Cowell Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis Oncogene 16 1998 2243 2248
135. X.H Wang S.C.H Wong J Pan S.W Tsao K.H.Y Fung D.L.W Kwong J.S.T Sham J.M Nicholls Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells Cancer Res. 58 1998 5019 5022
136. R Villa M Folini P Perego R Supino E Setti M.G Daidone F Zunino N Zaffaroni Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: Correlation with sensitivity to DNA damaging agents Int. J. Oncol. 16 2000 995 1002
137. Y Kiyozuka D Yamamoto J.H Yang Y Uemura H Senzaki S Adachi A Tsubura Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells Anticancer Res. 20 2000 003 212
138. H Mese Y Ueyama A Suzuki S Nakayama A Sasaki H Hamakawa T Matsumura Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line Chemotherapy 47 2001 136 142
139. 4 telomeric sequence: A structural and cross-linking study Biochemistry 40 2001 8463 8470
140. K Bouayadi P Calsou A.M Pedrini B Salles In vitro evolution of cisplatin DNA monoadducts into diadducts is dependent upon superhelical density Biochem. Biophys. Res. Commun. 189 1992 111 118
141. S Neumann H Simon C Zimmer A Quinones The antitumor agent cisplatin inhibits DNA gyrase and preferentially induces gyrB gene expression in Escherichia coli Biol. Chem. 377 1996 731 739
142. M Fukuda K Nishio F Kanzawa H Ogasawara T Ishida H Arioka K Bojanowski M Oka N Saijo Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells Cancer Res. 56 1996 789 793
143. N Masumoto S Nakano T Esaki H Fujishima T Tatsumoto Y Niho Inhibition of cis -diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST -1 human squamous-carcinoma cells Int. J. Cancer 62 1995 70 75
144. S Kobayashi M Furukawa C Dohi H Hamashima T Arai A Tanaka Topology effect for DNA structure of cisplatin: Topological transformation of cisplatin-closed circular DNA adducts by DNA topoisomerase I Chem. Pharm. Bull. 47 1999 783 790
145. 2 inhibit DNA synthesis in cultured L1210 leukemia cells Biochem. Biophys. Res. Commun. 112 1983 555 563
146. V.M Gonzalez M.A Fuertes C Alonso J.M Perez Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59 2001 657 663
147. F.A Blommaert H.C.M Van Dijk-Knijnenburg F.J Dijt L Denengelse R.A Baan F Berends A.M.J Fichtinger-Schepman Formation of DNA adducts by the anticancer drug carboplatin: Different nucleotide sequence preferences in vitro and in cells Biochemistry 34 1995 8474 8480
148. G Natarajan R Malathi E Holler Increased DNA binding activity of cis -1,1-cyclobutanedicarboxylatodiammineplatinum(II) (Carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: Activation theory revisited Biochem. Pharmacol. 58 1999 1625 1629
149. O Vrana V Brabec V Kleinwächter Polarographic studies on the conformation of some platinum complexes: relations to anti-tumour activity Anti-Cancer Drug Design 1 1986 95 109
150. M.S Highley A.H Calvert Clinical experience with cisplatin and carboplatin L.R Kelland N.P Farrell Platinum-Based Drugs in Cancer Therapy 2000 Humana Press Totowa, NJ 171 194
151. S.K Mauldin M Plescia F.A Richard S.D Wyrick R.D Voyksner S.G Chaney Displacement of the bidentate malonate ligand from (d,1- trans -1,2-diaminecyclohexane)malonatoplatinum(II) by physiologically important compounds in vitro Biochem. Pharmacol. 37 1998 3321 3333
152. J.M Woynarowski W.G Chapman C Napier M.C.S Herzig P Juniewicz Sequence-and region-specificity of oxaliplatin adducts in naked and cellular DNA Mol. Pharmacol. 54 1998 770 777
153. M.M Jennerwein A Eastman A Khokhar Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes Chem.-Biol. Interact. 70 1989 39 50
154. C.P Saris P.J.M van de Vaart R.C Rietbroek F.A Blommaert In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells Carcinogenesis 17 1996 2763 2769
155. E.D Scheeff J.M Briggs S.B Howell Molecular modeling of the intrastrand guanineguanine DNA adducts produced by cisplatin and oxaliplatin Mol. Pharmacol. 56 1999 633 643
156. A Vaisman S.E Lim S.M Patrick W.C Copeland D.C Hinkle J.J Turchi S.G Chaney Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts Biochemistry 38 1999 11,026 11,039
157. J.T Reardon A Vaisman S.G Chaney A Sancar Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Res. 59 1999 3968 3971
158. A Vaisman S.G Chaney The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta J. Biol. Chem. 275 2000 13,017 13,025
159. A Vaisman C Masutani F Hanaoka S.G Chaney Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta Biochemistry 39 2000 4575 4580
160. A Vaisman M.W Warren S.G Chaney The effect of DNA structure on the catalytic efficiency and fidelity of human DNA polymerase β on templates with platinum-DNA adducts J. Biol. Chem. 276 2001 18,999 19,005
161. S Nebel D Fink S Aebi A Nehme R.D Christen S.B Howell Role of the DNA mismatch repair proteins in the recognition of platinum DNA adducts 3rd ed. Proc. Am. Assoc. Cancer. Res. 38 1997 A2402
162. D Fink H Zheng S Nebel P.S Norris S Aebi T.P Lin A Nehme R.D Christen M Haas C.L MacLeod S.B Howell In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair Cancer Res. 57 1997 1841 1845
163. Y Kidani K Inagaki M Iigo A Hoshi K Kuretani Antitumor activity of 1,2-diamminocyclohexane-platinum complexes against Sarcoma 180 ascites form J. Med. Chem. 21 1978 1315 1318
164. M Coluccia M Correale D Giordano M.A Mariggio S Moscelli F.P Fanizzi G Natile L Maresca Mutagenic activity of some platinum complexes with monodentate and bidentate amines Inorg. Chim. Acta 123 1986 225 229
165. A Pasini F Zunino New cisplatin analogues—On the way to better antitumor agents Angew. Chem. Int. Ed. 26 1987 615 624
166. K Vickery A.M Bonin R.R Fenton S O'Mara P.J Russell L.K Webster T.W.J Hambley Preparation, characterization, cytotoxicity, and mutagenicity of a pair of enantiomeric platinum(H) complexes with the potential to bind enantioselectively to DNA J. Med. Chem. 36 1993 3663 3668
167. J.D Page I Husain A Sancar S.G Chaney Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality Biochemistry 29 1990 1016 1024
168. F.P Fanizzi F.P Intini L Maresca G Natile R Quaranata M Coluccia L Di Bari D Giordano M.A Mariggio Biological activity of platinum complexes containing chiral centers on the nitrogen or carbon atoms of a chelate diamine ring Inorg. Chim. Acta 137 1987 45 51
169. J Malina C Hofr L Maresca G Natile V Brabec DNA interactions of antitumor cisplatin analogs containing enantiomeric amine ligands Biophys. J. 78 2000 2008 2021
170. W.I Sundquist S.J Lippard The coordination chemistry of platinum anticancer drugs and related compounds with DNA Coord. Chem. Rev. 100 1990 293 322
171. M Broggini E Erba M Ponti D Ballinari C Geroni F Spreafico M Dincalci Selective DNA Interaction of the Novel Distamycin Derivative FCE 24517 Cancer Res. 51 1991 199 204
172. K.M Church R.L Wurdeman Y Zhang F.X Chen B Gold N-(2-chloroethyl)-Ntrosoureas covalently bound to nonionic and monocationic lexitropsin dipeptides. Synthesis, DNA affinity binding characteristics, and reactions with P-32-end-labeled DNA Biochemistry 29 1990 6827 6838
173. B.E Bowler L.S Hollis S.J Lippard Synthesis and DNA binding and photonicking properties of acridine orange linked by a polymethylene tether to (1,2-iaminoethane)dichloroplatinum(II) J. Am. Chem. Soc. 106 1984 6102 6104
174. C Zimmer Effects of the antibiotics netropsin and distamycin A on the structure and function of nucleic acids Prog. Nucleic Acid Res. Mol. Biol. 15 1975 285 318
175. C Zimmer U Wahnert Nonintercalating DNA-binding ligands: Specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material Prog. Biophys. Mol. Biol. 47 1986 31 112
176. M Lee J.E Simpson A.J Bums S Kupchinsky N Brooks J.A Hartley L.R Kelland Novel platinum(II) derivatives of analogues of netropsin and distamycin: Synthesis, DNA binding and cytotoxic properties Med. Chem. Res. 6 1996 365 371
177. H Loskotova V Brabec DNA interactions of cisplatin tethered to the DNA minor groove binder distamycin Eur. J. Biochem. 266 1999 392 402
178. H Kostrhunova V Brabec Conformational analysis of site-specific DNA cross-links of cisplatin-distamycin conjugates Biochemistry 39 2000 12,639 12,649
179. J Holford F Raynaud B.A Murrer K Grimaldi J.A Hartley M Abrams L.R Kelland Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis -[amminedichloro(2-methylpyridine)]platinum(II) (AMD473) Anti-Cancer Drug Design 13 1998 1 18
180. A Habtemariam P Sadler Design of chelate ring-opening platinum anticancer complexes: Reversible binding to guanine Chem. Commun. 1996 1785 1786
181. N Margiotta A Habtemariam P.J Sadler Strong, rapid binding of a platinum complex to thymine and uracil under physiological conditions Angew. Chem. Int. Ed. 36 1997 1185 1187
182. K Neplechova J Kasparkova O Vrana O Novakova A Habtemariam B Watchman P.J Sadler V Brabec DNA interactions of new antitumor aminophosphine platinum(II) complexes Mol. Pharmacol. 56 1999 20 30
183. L.R Kelland New platinum drugs. The pathway to oral therapy L.R Kelland N.P Farrell Platinum-Based Drugs in Cancer Therapy 2000 Humana Press Totowa, NJ 299 319
184. V Juraskova V Brabec Evaluation of cytotoxic and antitumour effects of tetravalent analog of carboplatin Neoplasma 36 1989 297 303
185. E Rotondo V Fimiani A Cavallaro T Ainis Does the antitumoral activity of platinum(IV) derivatives result from their in vivo reduction Tumori 69 1983 31 36
186. 2 and their reduction products with PM2 DNA Biochemistry 23 1984 4817 4820
187. L Pendyala A.V Arakali P Sansone J.W Cowens P.J Creaven DNA binding of iproplatin and its divalent metabolite cis -dichloro-bis-isopropylamine platinum(H) Cancer Chemother Pharmacol. 27 1990 248 250
188. L.R Kelland B.A Murrer G Abel C.M Giandomenico P Mistry K.R Harrap Ammine/Amine platinum(IV) dicarboxylates: A novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines Cancer Res. 52 1992 822 828
189. S.G Chaney S Wyrick G.K Till It vitro biotransformations of tetrachloro (d,1-trans)-1, 2-diaminocyclohex aneplatinum(IV) (tetraplatin) in rat plasma Cancer Res. 50 1990 4539 4545
190. M Defais M Germanier N.P Johnson Detection of DNA strand breaks in Escherichia Coli treated with platinum(IV) antitumor compounds Chem.-Biol. Interact. 74 1990 343 352
191. H.K Choi S.K.-S Huang R Bau Octahedral complex of anticancer Pt(IV)(cyclohexyldiamine) agents with 9-methylguanine Biochem. Biophys. Res. Commun. 156 1988 1125 1129
192. 3]CI), with purine nucleosides and nucleotides results in formation of platinum(H) as well as platinum(IV) complexes J. Inorg. Biochem. 52 1993 263 274
193. O Novakova O Vrana V.I Kiseleva V Brabec DNA interactions of antitumor platinum(IV) complexes Eur. J. Biochem. 228 1995 616 624
194. K.J Mellish C.F.J Barnard B.A Murrer L.R Kelland DNA-binding properties of novel cis - and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines Int. J. Cancer 62 1995 717 723
195. W.I Sundquist L Bancroft L Chassot S.J Lippard DNA promotes the reaction of cis -diamminedichloroplatinum(II) with the exocyclic amino groups of ethidium bromide J. Am. Chem. Soc. 110 1988 8559 8561
196. M Boudvillain R Dalbies M Leng Evidences for a catalytic activity of the DNA double helix in the reaction between DNA, platinum(H), and intercalators A Sigel H Sigel Metal Ions in Biological Systems 1996 Dekker New York 87 104
197. + J. Med. Chem. 32 1989 128 136
198. L.S Hollis W.I Sundquist J.N Burstyn W.J Heiger-Bemays S.R Bellon K.J Ahmed A.R Amundsen E.W Stem S.J Lippard Mechanistic studies of a novel class of trisubstituted platinum(H) antitumor agents Cancer Res. 51 1991 1866 1875
199. C Bauer T Peleg-Shulman D Gibson A.H.-J Wang Monofunctional platinum amine complexes destabilize DNA significantly Eur. J. Biochem. 256 1998 253 260
200. T Peleg-Shulman J Katzhendler D Gibson Effects of monofunctional platinum binding on the thermal stability and conformation of a self-complementary 22-mer J. Inorg. Biochem. 81 2000 313 323
201. R.C Taylor S.G Ward M Nicolini L Sindellari 3rd ed. Lectures in Bioinorganic Chemistry 1991 Raven Press New York 63 90
202. M Coluccia A Boccarelli C Cermelli M Portolani G Natile Platinum(II)acyclovir complexes: Synthesis, antiviral and antitumour activity Metal-Based Drugs 2 1995 249 256
203. + Mol. Pharmacol. 53 1998 846 855
204. N Farrell Current status of structure-activity relationships of platinum anticancer drugs: Activation of the trans geometry A Sigel H Sigel Metal Ions in Biological Systems 1996 Dekker New York/Basel/Hong Kong 603 639
205. 3)(quinoline)] Eur. J. Biochem. 254 1998 547 557
206. V Brabec K Neplechova J Kasparkova N Farrell Steric control of DNA interstrand cross-link sites of trans platinum complexes: Specificity can be dictated by planar nonleaving groups J. Biol. Inorg. Chem. 5 2000 364 368
207. M Coluccia A Boccarelli M.A Mariggio N Cardellicchio P Caputo F.P Intini G Natile Platinum(H) complexes containing iminoethers: A trans platinum antitumour agent Chem.-Biol. Interact. 98 1995 251 266
208. 2] Nucleic Acids Res. 24 1996 336 341
209. 2] Mol. Pharmacol. 52 1997 354 361
210. B Andersen N Margiotta M Coluccia G Natile E Sletten Antitumor trans platinum DNA adducts: N MR and HPLC study of the interaction between a trans -Pt iminoether complex and the deoxy decamer d(CCTCGCTCTC)·d(GAGAGCGAGG) Metal-Based Drugs 7 2000 23 32
211. 2(dimethylamine) (isopropylamine)]: Interstrand cross-link efficiency, DNA sequence specificity, and inhibition of the B-Z transition J. Med. Chem. 43 2000 2411 2418
212. 2(isopropylamine)(amine)] complexes J. Inorg. Biochem. 77 1999 37 42
213. 2(amine)(isopropylamine)] compounds: Cytotoxic activity and apoptosis induction in ras -transformed cells J. Med. Chem. 42 1999 4264 4268
214. N Farrell Polynuclear charged platinum compounds as a new class of anticancer agents: Toward a new paradigm L.R Kelland N.P Farrell Platinum-Based Drugs in Cancer Therapy 2000 Humana Press Totowa, NJ 321 338
215. N Farrell Y Qu U Bierbach M Valsecchi E Menta Structure-activity relationship within di- and trinuclear platinum phase I clinical agents B Lippert Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug 1999 VHCA, Wiley-VCH Zürich/Weinheim 479 496
216. J Kasparkova K.J Mellish Y Qu V Brabec N Farrell Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies Biochemistry 35 1996 16,705 16,713
217. K.J Mellish Y Qu N Scarsdale N Farrell Effect of geometric isomerism in dinuclear platinum antitumour complexes on the rate of formation and structure of intrastrand adducts with oligonucleotides Nucleic Acids Res. 25 1997 1265 1271
218. J Kasparkova O Novakova O Vrana N Farrell V Brabec Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking Biochemistry 38 1999 10,997 11,005
219. J Kasparkova N Farrell V Brabec Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes J. Biol. Chem. 275 2000 15,789 15,798
220. R Zaludova A Zakovska J Kasparkova Z Balcarova V Kleinwächter O Vrana N Farrell V Brabec DNA interactions of bifunctional dinuclear platinum(II) antitumor agents Eur. J. Biochem. 246 1997 508 517
221. Y Zou B Vanhouten N Farrell Sequence specificity of DNA-DNA interstrand crosslink formation by cisplatin and dinuclear platinum complexes Biochemistry 33 1994 5404 5410
222. T.D. McGregor, J. Kasparkova, K. Neplechova, O. Novakova, H. Penazova, O. Vrana, V. Brabec, and N. Farrell, A. Comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers and the trinuclear platinum phase II clinical agent BBR3464. J. Biol. Inorg. Chem. Published online, D01 10.1007s 00775-001-0312-4.
223. V Brabec J Kasparkova O Vrana O Novakova J.W Cox Y Qu N Farrell DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent Biochemistry 38 1999 6781 6790
224. J Zehnulova J Kasparkova N Farrell V Brabec Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464 J. Biol. Chem. 276 2001 22,91 22199
225. M.J Clarke F Zhu D.R Frasca Non-platinum chemotherapeutic metallopharmaceuticals Chem. Rev. 99 1999 2511 2533
226. B.K Keppler K.-G Lipponer B Stenzel F Kratz New tumor-inhibiting ruthenium complexes B Keppler Metal complexes in cancer chemotherapy 1993 VCH Verlagsgesellschaft, VCH Publishers Weinheim/New York 187 220
227. G Sava E Alessio A Bergano G Mestroni Sulfoxide ruthenium complexes: Nontoxic tools for the selective treatment of solid tumour metastases M.J Clarke P.J Sadler Topics in Biological Inorganic Chemistry. Metallopharmaceuticals 1999 Springer Berlin 143 169
228. G Mestroni E Alessio M Calligaris W.M Attia F Quadrifoglio S Cauci G Sava S Zorzet S Pacor C Monti-Bragadin M Tamaro L Dolzani Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethylsulfoxide Prog. Clin. Biochem. Med. 10 1989 71 87
229. 4 isomers with DNA Anticancer Res. 11 1991 1549 1553
230. 4Ru] in cell-free media Biochem. Pharmacol. 60 2000 1761 1771
231. Y.N.V Gopal D Jayaraju A.K Kondapi Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: A ligand-dependent mode of action Biochemistry 38 1999 4382 4388
232. B.K Keppler Metal Complexes in Cancer Chemotherapy 1993 VCH Verlagsgesellschaft, VCH Publishers Weinheim/New York
233. J Malina O Novakova B.K Keppler E Alessio V Brabec Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media J. Biol. Inorg. Chem. 6 2001 435 445
234. J.K Barton Metals and DNA: Molecular left-handed complements Science 233 1986 727 734
235. N Grover T.W Welch T.A Fairley M Cory H.H Thorp Covalent binding of aquaruthenium complexes to DNA Inorg. Chem. 33 1994 3544 3548
236. G.A Neyhart C.C Cheng H.H Thorp Kinetics and mechanism of the oxidation of sugars and nucleotides by oxoruthenium(IV): Model studies for predicting cleavage patterns in polymeric DNA and RNA J. Am. Chem. Soc. 117 1995 1463 1471
237. J.K Barton E Lolis Chiral discrimination in the covalent binding of bis(phenanthroline) dichlororuthenium(II) to B-DNA J. Am. Chem. Soc. 107 1985 708 709
238. O Novakova J Kasparkova O Vrana P.M van Vliet J Reedijk V Brabec Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes Biochemistry 34 1995 12,69 12378
239. 3] (terpy = 2,2′:6′,2′′-terpyridine) shows biological activity, forms interstrand cross-links in DNA and binds two guanine derivatives in a trans configuration Inorg. Chim. Acta 231 1995 57 65
240. B Van Houten S Illenye Y Qu N Farrell Homodinuclear (Pt,Pt) and heterodinuclear (Ru,Pt) metal compounds as DNA-protein cross-linking agents: Potential suicide DNA lesions Biochemistry 32 1993 11,94 11801
241. P.M Takahara A.C Rosenzweig C.A Frederick S.J Lippard Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin Nature 377 1995 649 652